![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NAA35 |
Gene summary for NAA35 |
![]() |
Gene information | Species | Human | Gene symbol | NAA35 | Gene ID | 60560 |
Gene name | N-alpha-acetyltransferase 35, NatC auxiliary subunit | |
Gene Alias | EGAP | |
Cytomap | 9q21.33 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A8K874 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
60560 | NAA35 | P1_cSCC | Human | Skin | cSCC | 6.97e-11 | 3.85e-01 | 0.0292 |
60560 | NAA35 | P2_cSCC | Human | Skin | cSCC | 8.57e-03 | 1.57e-01 | -0.024 |
60560 | NAA35 | P4_cSCC | Human | Skin | cSCC | 1.48e-05 | 2.43e-01 | -0.00290000000000005 |
60560 | NAA35 | P10_cSCC | Human | Skin | cSCC | 2.65e-11 | 4.16e-01 | 0.1017 |
60560 | NAA35 | male-WTA | Human | Thyroid | PTC | 6.71e-17 | 4.72e-02 | 0.1037 |
60560 | NAA35 | PTC01 | Human | Thyroid | PTC | 1.09e-08 | 7.68e-02 | 0.1899 |
60560 | NAA35 | PTC04 | Human | Thyroid | PTC | 3.29e-10 | 1.55e-01 | 0.1927 |
60560 | NAA35 | PTC05 | Human | Thyroid | PTC | 3.22e-15 | 5.32e-01 | 0.2065 |
60560 | NAA35 | PTC06 | Human | Thyroid | PTC | 6.12e-11 | 3.13e-01 | 0.2057 |
60560 | NAA35 | PTC07 | Human | Thyroid | PTC | 6.65e-21 | 2.51e-01 | 0.2044 |
60560 | NAA35 | ATC12 | Human | Thyroid | ATC | 8.35e-15 | 3.00e-01 | 0.34 |
60560 | NAA35 | ATC13 | Human | Thyroid | ATC | 6.83e-20 | 3.66e-01 | 0.34 |
60560 | NAA35 | ATC2 | Human | Thyroid | ATC | 9.17e-10 | 5.45e-01 | 0.34 |
60560 | NAA35 | ATC3 | Human | Thyroid | ATC | 2.30e-02 | 9.72e-02 | 0.338 |
60560 | NAA35 | ATC4 | Human | Thyroid | ATC | 1.11e-17 | 3.89e-01 | 0.34 |
60560 | NAA35 | ATC5 | Human | Thyroid | ATC | 2.78e-29 | 3.97e-01 | 0.34 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0033002 | Cervix | CC | muscle cell proliferation | 49/2311 | 248/18723 | 5.43e-04 | 5.24e-03 | 49 |
GO:00516048 | Cervix | CC | protein maturation | 56/2311 | 294/18723 | 5.90e-04 | 5.59e-03 | 56 |
GO:00486593 | Cervix | CC | smooth muscle cell proliferation | 36/2311 | 184/18723 | 3.27e-03 | 2.13e-02 | 36 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:00182061 | Esophagus | ESCC | peptidyl-methionine modification | 12/8552 | 13/18723 | 6.18e-04 | 3.32e-03 | 12 |
GO:00486597 | Esophagus | ESCC | smooth muscle cell proliferation | 103/8552 | 184/18723 | 3.08e-03 | 1.28e-02 | 103 |
GO:00330025 | Esophagus | ESCC | muscle cell proliferation | 134/8552 | 248/18723 | 4.80e-03 | 1.86e-02 | 134 |
GO:0031365 | Esophagus | ESCC | N-terminal protein amino acid modification | 21/8552 | 30/18723 | 6.17e-03 | 2.27e-02 | 21 |
GO:0006474 | Esophagus | ESCC | N-terminal protein amino acid acetylation | 13/8552 | 17/18723 | 1.00e-02 | 3.42e-02 | 13 |
GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
GO:00064734 | Oral cavity | OSCC | protein acetylation | 124/7305 | 201/18723 | 5.59e-11 | 1.74e-09 | 124 |
GO:00486596 | Oral cavity | OSCC | smooth muscle cell proliferation | 89/7305 | 184/18723 | 5.95e-03 | 2.27e-02 | 89 |
GO:00330024 | Oral cavity | OSCC | muscle cell proliferation | 115/7305 | 248/18723 | 1.05e-02 | 3.58e-02 | 115 |
GO:003300212 | Oral cavity | EOLP | muscle cell proliferation | 56/2218 | 248/18723 | 1.25e-06 | 3.00e-05 | 56 |
GO:004865915 | Oral cavity | EOLP | smooth muscle cell proliferation | 44/2218 | 184/18723 | 3.47e-06 | 7.48e-05 | 44 |
GO:004354321 | Oral cavity | EOLP | protein acylation | 51/2218 | 243/18723 | 3.11e-05 | 4.41e-04 | 51 |
GO:000647321 | Oral cavity | EOLP | protein acetylation | 44/2218 | 201/18723 | 3.69e-05 | 5.12e-04 | 44 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NAA35 | SNV | Missense_Mutation | novel | c.1520N>A | p.Gly507Asp | p.G507D | Q5VZE5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NAA35 | SNV | Missense_Mutation | c.1795N>T | p.Asp599Tyr | p.D599Y | Q5VZE5 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD | |
NAA35 | SNV | Missense_Mutation | c.1951N>G | p.Gln651Glu | p.Q651E | Q5VZE5 | protein_coding | tolerated(1) | benign(0.001) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
NAA35 | SNV | Missense_Mutation | c.1307N>G | p.Ile436Ser | p.I436S | Q5VZE5 | protein_coding | deleterious(0.01) | possibly_damaging(0.68) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
NAA35 | SNV | Missense_Mutation | rs138043991 | c.1288N>T | p.Arg430Trp | p.R430W | Q5VZE5 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NAA35 | SNV | Missense_Mutation | c.250N>A | p.Leu84Ile | p.L84I | Q5VZE5 | protein_coding | tolerated(0.17) | benign(0.406) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
NAA35 | SNV | Missense_Mutation | rs776821188 | c.1889C>T | p.Pro630Leu | p.P630L | Q5VZE5 | protein_coding | deleterious(0) | benign(0.301) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NAA35 | SNV | Missense_Mutation | c.242G>A | p.Arg81Gln | p.R81Q | Q5VZE5 | protein_coding | tolerated(0.1) | benign(0.152) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
NAA35 | SNV | Missense_Mutation | c.1709N>A | p.Arg570His | p.R570H | Q5VZE5 | protein_coding | tolerated(0.08) | benign(0.125) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
NAA35 | SNV | Missense_Mutation | c.434C>T | p.Ala145Val | p.A145V | Q5VZE5 | protein_coding | tolerated(1) | benign(0.023) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |